SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
Level 5, 115 Grenfell Street, Adelaide SA 5000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 06/11/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 31/10/2024 |
The company has lodged financial reports with ASIC. | 15/10/2024 |
The company notifies ASIC of the appointment or cessation of a director or company secretary. | 10/10/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 02/10/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 14/08/2024 |
ASIC is notified of the resignation of the company's auditor. | 20/06/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 17/06/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 20/02/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 19/02/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 16/02/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 09/02/2024 |
Company lodges a form with ASIC being a notification of the issue of shares. | 05/02/2024 |
The company notifies ASIC of changes to its share structure which may include changes to the class of shares (e.g. converting ordinary shares to preference shares), amendments to the terms on which shares are issued, or the consolidation/splitting of shares. | 05/02/2024 |
Company reports the following corporate highlights: In support of the Company's transformation into a commercial-stage company, expanded the U.S.-based team with new highly experienced management appointments, positioning it to become a leading company in neuropsychiatry. Voluntarily delisted from the Australian Stock Exchange in August 2023 and is currently solely listed on the NASDAQ Global Market. Further reduced cash burn through efficient capital allocation. Maintained its current institutional investors' support while adding new institutional investors to its register. Sustained strong analyst coverage that highlights the Company's potential future value. The Company has no outstanding debt, convertible securities, or warrants. Continued strengthening BNC210 intellectual property portfolio in the U.S. and abroad. | 22/01/2024 |
delisted at entity's request under Listing Rule 17.11 | 28/08/2023 |
we understand the company delisted because of low trading volumes on ASX, costs of the listing, leverage gained from the US institutional base, location of directors and management and the geographic location of the largest shareholders - Nasdaq is now its sole listing | 28/08/2023 |
The securities of Bionomics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of BNO, to facilitate its removal from the official list of ASX Limited. | 25/08/2023 |
shares reinstated to quotation | 08/09/2009 |
shares suspended from quotation following an announcement of an acquisition | 07/09/2009 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 20/12/2021 | Alan Fisher | 100,000 | $0.120 | $12,000.00 |
| 14/09/2016 | Peter Turner | 100,000 | $0.289 | $28,944.00 |
| 01/09/2016 | Deborah Rathjen | 100,000 | $0.247 | $24,735.00 |
| 12/08/2016 | David Ian Wilson | 200,000 | $0.284 | $56,720.00 |
| 11/12/2015 | Deborah Rathjen | 105,500 | $0.390 | $41,178.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Alan Fisher | Non Exec Chairman | 31/08/2016 |
| Tim Cunningham | CFO | 01/07/2023 |
| Aaron Weaver | Non Exec Director | 06/07/2020 |
| Errol De Souza | Non Exec Director | 28/02/2008 |
| Jane Ryan | Non Exec Director | 01/10/2020 |
| David Ian Wilson | Non Exec Director | 16/06/2016 |
| Miles Davies | Non Exec Director | 01/07/2021 |
| Suzanne Irwin | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
